FDA Approval for Medtronic Attain Performa® Quadripolar Lead and Viva® Quad CRT-Ds

Medtronic, Inc. has received U.S. FDA approval for the Attain Performa® Model 4298 quadripolar lead, and the Viva® Quad XT and Viva® Quad S cardiac resynchronization therapy defibrillators (CRT-D). The quadripolar lead and devices will be broadly available to physicians in mid-September.


Medtronic says its Attain Performa lead addresses the clinical challenges that can compromise lead position, offering implanting physicians more options to maintain lead position and optimize CRT therapy. The Model 4298 lead has a canted shape, and steroid on all four electrodes for lower pacing thresholds.

With 16 pacing configurations and shorter spacing between the two center electrodes, the Attain Performa Model 4298 left-heart lead provides additional options for physicians to treat different patient anatomies. The new quadripolar lead reduces the incidence of phrenic nerve stimulation (PNS), a potential side effect that results in muscle twitching, hiccups or shortness of breath.

The Viva Quad XT device is equipped with the proprietary AdaptivCRT feature, which preserves normal heart rhythms and automatically adjusts to patients’ needs to customize therapy. The system includes VectorExpress™ technology, which reduces lead programming time to two minutes by providing physicians with clinically actionable information to help them select optimal pacing configurations for each patient.

Physician comments

“Compared to conventional leads, the additional pacing configurations offered by this system provide implanting physicians more options to optimize CRT delivery, which results in better patient care. Likewise, the narrow-spaced bipole helps avoid phrenic nerve capture,” said George H. Crossley, M.D., F.A.C.C., F.H.R.S., associate professor, Vanderbilt Heart and Vascular Institute, in Nashville, Tenn.

Company comments

“Medtronic continues to advance the care of heart failure patients, as it has since it first commercialized cardiac resynchronization therapy in the U.S. With the previously available AdaptivCRT algorithm, and now the new Attain Performa canted lead and Viva Quad devices, Medtronic is delivering a top-notch system for patients with heart failure,” said David Steinhaus, M.D., vice president and general manager, Heart Failure, and medical director for the Cardiac Rhythm and Heart Failure Management business at Medtronic.

Source: Medtronic, Inc.

Share your thoughts

Your email address will not be published. Required fields are marked *